Health ❯ Healthcare ❯ Oncology

Targeted Therapy

HER2 Mutations Fruquintinib PIK3CA Mutations EGFR Mutations Everolimus ADC (Antibody-Drug Conjugate) DLL3-Targeted Treatments Zanzalintinib MET Inhibitors BRAF V600E Mutation DNA Damage Response KRAS Gene Mutations KRAS Pathway KRAS Protein Mirvetuximab Soravtansine HER2-positive Cancer

8 ARTICLES

last mo.

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

Based on Phase III survival gains, the agency added boxed warnings for severe diarrhea and embryo‑fetal harm that will shape how clinicians use the new regimens.

7 ARTICLES

4mo ago

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

3 ARTICLES

last yr.

Targeted Therapy

FDA Approves Zanidatamab Regimens for First‑Line HER2‑Positive Gastroesophageal Cancer

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Everolimus Plus Carboplatin Delays Progression in Advanced Triple-Negative Breast Cancer, Phase 2 Study Shows